We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
Read MoreHide Full Article
PDL BioPharma, Inc. (PDLI - Free Report) delivered earnings of 9 cents per share in the third quarter of 2018, beating the Zacks Consensus Estimate of 7 cents. However, the bottom line was lower than 14 cents in the year-ago period.
The company’s total revenues grossed $67.9 million in the reported quarter, reflecting an 8.2% increase year over year. This upside is mainly attributable to a sharp rise in royalties as well as product revenues.
Higher royalties are because of an increase in value of royalty rights from Depomed. In August, the company paid $20 million to buy Depomed's remaining 50% interest in royalties payable on sales of the type II diabetes products licensed by Depomed. Following the amendment, PDL now receives 100% royalties rather than a 50/50 share with Depomed.
Shares of PDL BioPharma were up almost 18% following its earnings release on Nov 6. In fact, the stock has gained 5.9% so far this year against the industry’s decline of 16.4%.
Quarter in Detail
Product revenues for the quarter under review were $24.4 million, up 21.5% year over year. The same included $17.8 million from the sales of Noden products — Tekturna and Tekturna HCT — and $6.6 million from the sales of LENSAR laser system in the United States.
PDL recognized $42.2 million in revenues from royalty rights, $0.5 million of royalties from PDL's licensees to the Queen et al. patents and $0.8 million of interest revenues.
Royalty revenues from the Queen et al. licenses were lower than the year-ago period, mainly due to lower product supplies of Biogen’s (BIIB - Free Report) multiple sclerosis drug, Tysabri.
Research and development (R&D) expenses for the third quarter summed $0.7 million, up 11.1% from the prior-year level. This upside was owing to a contribution of additional cost of product revenues from Noden products and LENSAR laser system in ex-U.S. markets
General and administrative expenses escalated 10.9% to $13.9 million from the level registered in comparable quarter last year.
In September 2018, PDL BioPharma announced that its board of directors approved a new $100 million worth share buyback program of the company's common stock. This is the third and the largest stock repurchase program after having completed a $30-million program in June 2017 and a subsequent $25-million program in third-quarter 2018. The company expects to have substantial cash in hand to execute this strategy.
Along with earnings release, PDL BioPharma reported that its president Dominique Monnet will assume the role of chief executive officer (CEO) following its current CEO John P. McLaughlin’s retirement at this year-end.
PDL BioPharma, Inc. Price, Consensus and EPS Surprise
PDL BioPharma currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are Gilead Sciences, Inc. (GILD - Free Report) and Alexion Pharmaceuticals, Inc. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences’ earnings estimates have been revised 4.4% upward for 2018 and 4.2% for 2019 over the past 60 days.The stock has inched up 1.2% so far this year.
Alexion’s earnings estimates have moved 4.8% north for 2018 and 1.8% for 2019 over the past 60 days. The stock has gained 6.4% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
PDL BioPharma, Inc. (PDLI - Free Report) delivered earnings of 9 cents per share in the third quarter of 2018, beating the Zacks Consensus Estimate of 7 cents. However, the bottom line was lower than 14 cents in the year-ago period.
The company’s total revenues grossed $67.9 million in the reported quarter, reflecting an 8.2% increase year over year. This upside is mainly attributable to a sharp rise in royalties as well as product revenues.
Higher royalties are because of an increase in value of royalty rights from Depomed. In August, the company paid $20 million to buy Depomed's remaining 50% interest in royalties payable on sales of the type II diabetes products licensed by Depomed. Following the amendment, PDL now receives 100% royalties rather than a 50/50 share with Depomed.
Shares of PDL BioPharma were up almost 18% following its earnings release on Nov 6. In fact, the stock has gained 5.9% so far this year against the industry’s decline of 16.4%.
Quarter in Detail
Product revenues for the quarter under review were $24.4 million, up 21.5% year over year. The same included $17.8 million from the sales of Noden products — Tekturna and Tekturna HCT — and $6.6 million from the sales of LENSAR laser system in the United States.
PDL recognized $42.2 million in revenues from royalty rights, $0.5 million of royalties from PDL's licensees to the Queen et al. patents and $0.8 million of interest revenues.
Royalty revenues from the Queen et al. licenses were lower than the year-ago period, mainly due to lower product supplies of Biogen’s (BIIB - Free Report) multiple sclerosis drug, Tysabri.
Research and development (R&D) expenses for the third quarter summed $0.7 million, up 11.1% from the prior-year level. This upside was owing to a contribution of additional cost of product revenues from Noden products and LENSAR laser system in ex-U.S. markets
General and administrative expenses escalated 10.9% to $13.9 million from the level registered in comparable quarter last year.
In September 2018, PDL BioPharma announced that its board of directors approved a new $100 million worth share buyback program of the company's common stock. This is the third and the largest stock repurchase program after having completed a $30-million program in June 2017 and a subsequent $25-million program in third-quarter 2018. The company expects to have substantial cash in hand to execute this strategy.
Along with earnings release, PDL BioPharma reported that its president Dominique Monnet will assume the role of chief executive officer (CEO) following its current CEO John P. McLaughlin’s retirement at this year-end.
PDL BioPharma, Inc. Price, Consensus and EPS Surprise
PDL BioPharma, Inc. Price, Consensus and EPS Surprise | PDL BioPharma, Inc. Quote
Zacks Rank & Stocks to Consider
PDL BioPharma currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the healthcare sector are Gilead Sciences, Inc. (GILD - Free Report) and Alexion Pharmaceuticals, Inc. , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences’ earnings estimates have been revised 4.4% upward for 2018 and 4.2% for 2019 over the past 60 days.The stock has inched up 1.2% so far this year.
Alexion’s earnings estimates have moved 4.8% north for 2018 and 1.8% for 2019 over the past 60 days. The stock has gained 6.4% so far this year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>